Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lailotinib
- Development stage
- Unknown
- Lead developer
- Guangdong Dongyangguang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lailotinib (HEC74647) is an orally bioavailable, small-molecule multi-kinase inhibitor developed by Guangdong Dongyangguang Pharmaceutical (HEC Pharm). It acts as a potent inhibitor of the Fibroblast Growth Factor Receptor (FGFR) family, including FGFR1, FGFR2, and FGFR3, as well as the Vascular Endothelial Growth Factor Receptor (VEGFR) and Platelet-Derived Growth Factor Receptor (PDGFR). By blocking these signaling pathways, lailotinib inhibits both tumor cell growth and the formation of new blood vessels (angiogenesis) within the tumor microenvironment. The drug is currently undergoing clinical evaluation in China for the treatment of advanced solid tumors, particularly those harboring FGFR genetic alterations.
- Other names
- lailotinib
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)PDGFR (PDGFR family)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)VEGFR (VEGFR family)
Beyond the preview
Go deeper on lailotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lailotinib.